UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For Quarterly Period Ended ~~June~~September 30, 2022

☐

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period From to

Commission File Number 0-14602

CYANOTECH CORPORATION

(Exact name of registrant as specified in its charter)

Nevada	91-1206026
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification Number)

73-4460 Queen Kaahumanu Hwy. #102, Kailua-Kona, HI 96740

(Address of principal executive offices)

(808) 326-1353

(Registrant’s telephone number)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.02 par value per share	CYAN	NASDAQ

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☐		Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~August 5,~~November 4, 2022, the number of shares outstanding of the registrant’s common stock was ~~6,207,482.~~6,271,971.

Table of Contents

This Report and other presentations made by Cyanotech Corporation (“CYAN”) and its subsidiary contain “forward-looking statements,” which include statements that are predictive in nature, depend upon or refer to future events or conditions, and usually include words such as “expects,” “anticipates,” “intends,” “plan,” “believes,” “predicts”, “estimates” or similar expressions. In addition, any statement concerning future financial performance, ongoing business strategies or prospects and possible future actions are also forward-looking statements. Forward-looking statements are based upon current expectations and projections about future events and are subject to risks, uncertainties and the accuracy of assumptions concerning CYAN and its subsidiary (collectively, the “Company”), the performance of the industry in which CYAN does business, and economic and market factors, among other things. These forward-looking statements are not guarantees of future performance. You should not place undue reliance on forward-looking statements.

Forward-looking statements speak only as of the date of the Report, presentation or filing in which they are made. Except to the extent required by the Federal Securities Laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Our forward-looking statements in this Report include, but are not limited to:

These forward-looking statements are subject to risk, uncertainties and assumptions about us and our operations that are subject to change based on various important factors, some of which are beyond our control, including those factors described in Item 2 of Part I of this quarterly report and in Item 1A of Part I of the Company’s Annual Report on Form 10-K filed on June 22, 2022. Additionally, the following factors, among others, could cause our financial performance to differ significantly from the goals, plans, objectives, intentions and expectations expressed in our forward-looking statements:

It is not possible to predict or identify all potential risks and uncertainties and the above referenced factors and list do not comprise a complete list of all potential risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in any forward-looking statement contained in this report. All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report. Throughout this report, Cyanotech Corporation, together with its subsidiary, are referred to as “the Company.”

	June 30, 2022			March 31, 2022			September 30, 2022			March 31, 2022
ASSETS
Current assets:
Cash	$	737		$	2,589		$	379		$	2,589
Accounts receivable, net of allowance for doubtful accounts of $67 as of June 30, 2022 and March 31, 2022		3,201			3,664
Accounts receivable, net of allowance for doubtful accounts of $67 as of September 30, 2022 and March 31, 2022								2,118			3,664
Inventories		10,699			9,466			12,088			9,466
Prepaid expenses and other current assets		386			545			356			545
Total current assets		15,023			16,264			14,941			16,264

Equipment and leasehold improvements, net		11,916			11,885			11,747			11,885
Operating lease right-of-use assets, net		3,682			3,787			3,573			3,787
Other assets		95			109			92			109
Total assets	$	30,716		$	32,045		$	30,353		$	32,045

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,927		$	2,362		$	1,544		$	2,362
Accrued expenses		1,337			1,412			1,078			1,412
Customer deposits		79			164			92			164
Operating lease obligations, current portion		344			393			294			393
Line of credit								1,300			—
Current maturities of long-term debt		386			490			277			490
Total current liabilities		4,073			4,821			4,585			4,821

Long-term debt, less current maturities		4,273			4,336			4,212			4,336
Long-term operating lease obligations		3,325			3,386			3,265			3,386
Other long-term liabilities		11			15			5			15
Total liabilities		11,682			12,558			12,067			12,558

Commitments and contingencies

Stockholders’ equity:
Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding		0			0			—			—
Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 6,203,643 shares at June 30, 2022 and 6,202,223 shares at March 31, 2022		124			124
Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 6,271,971 shares at September 30, 2022 and 6,202,223 shares at March 31, 2022								125			124
Additional paid-in capital		33,576			33,557			33,767			33,557
Accumulated deficit		(14,666	)		(14,194	)		(15,606	)		(14,194	)
Total stockholders’ equity		19,034			19,487			18,286			19,487
Total liabilities and stockholders’ equity	$	30,716		$	32,045		$	30,353		$	32,045

	Common Stock Shares			Common Stock Amount		Additional Paid-in Capital			Accumulated Deficit			Total Stockholders’ Equity			Common Stock Shares			Common Stock Amount		Additional Paid-in Capital			Accumulated Deficit			Total Stockholders’ Equity
	(in thousands, except per share data)														(in thousands, except per share data)
Balances at March 31, 2022		6,202,223		$	124	$	33,557		$	(14,194	)	$	19,487
Balances at June 30, 2022																6,203,643		$	124	$	33,576		$	(14,666	)	$	19,034
Issuances of common stock for Director Stock Grants																64,489			1		157			—			158
Issuances of vested shares of restricted stock		2,277			—		(3	)		—			(3	)		6,035			—		(7	)		—			(7	)
Shares withheld for tax payments		(857	)		—		—			—			—			(2,196	)		—		—			—			—
Share-based compensation expense		—			—		22			—			22			—			—		41			—			41
Net loss		—			—		—			(472	)		(472	)		—			—		—			(940	)		(940	)
Balances at June 30, 2022		6,203,643		$	124	$	33,576		$	(14,666	)	$	19,034
Balances at September 30, 2022																6,271,971		$	125	$	33,767		$	(15,606	)	$	18,286

Balances at March 31, 2021		6,116,073		$	122	$	33,267		$	(16,348	)	$	17,041
Balances at June 30, 2021																6,117,719		$	122	$	33,285		$	(15,827	)	$	17,580
Issuances of vested shares of restricted stock		2,541			—		(3	)		—			(3	)		32,210			1		(37	)		—			(36	)
Shares withheld for tax payments		(895	)		—		—			—			—			(11,201	)		—		—			—			—
Share-based compensation expense		—			—		21			—			21			—			—		99			—			99
Net income		—			—		—			520			520			—			—		—			970			970
Balances at June 30, 2021		6,117,719		$	122	$	33,285		$	(15,828	)	$	17,579
Balances at September 30, 2021																6,138,728		$	123	$	33,347		$	(14,857	)	$	18,613

	Common Stock Shares			Common Stock Amount		Additional Paid-in Capital			Accumulated Deficit			Total Stockholders’ Equity
	(in thousands, except per share data)
Balances at March 31, 2022		6,202,223		$	124	$	33,557		$	(14,194	)	$	19,487
Issuance of common stock for Director Stock Grants		64,489			1		157			—			158
Issuance of vested shares of restricted stock		8,312			—		(10	)		—			(10	)
Shares withheld for tax payments		(3,053	)		—		—			—			—
Share-based compensation expense		—			—		63			—			63
Net loss		—			—		—			(1,412	)		(1,412	)
Balances at September 30, 2022		6,271,971		$	125	$	33,767		$	(15,606	)	$	18,286

Balances at March 31, 2021		6,116,073		$	122	$	33,267		$	(16,348	)	$	17,041
Issuance of vested shares of restricted stock		34,751			1		(40	)		—			(39	)
Shares withheld for tax payments		(12,096	)		—		—			—			—
Share-based compensation expense		—			—		120			—			120
Net income		—			—		—			1,491			1,491
Balances at September 30, 2021		6,138,728		$	123	$	33,347		$	(14,857	)	$	18,613

	Three Months Ended June 30,						Six Months Ended September 30,
	2022			2021			2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$	(472	)	$	520		$	(1,412	)	$	1,491
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization		417			400			834			798
Amortization of debt issue costs and other assets		13			17			23			32
Amortization of operating leases right-of-use assets		105			82			214			144
Share-based compensation expense		22			21			221			120
Provision for doubtful accounts		—			43			—			85
Net (increase) decrease in assets:
Accounts receivable		463			(2,643	)		1,546			(726	)
Inventories		(1,233	)		(819	)		(2,622	)		(897	)
Prepaid expenses and other assets		168			103			197			134
Net increase (decrease) in liabilities:
Accounts payable		(509	)		186			(826	)		(992	)
Accrued expenses		(75	)		289			(334	)		406
Customer deposits		(85	)		32			(72	)		(14	)
Operating lease obligations		(110	)		(85	)		(220	)		(147	)
Deferred rent and other liabilities		(3	)		(4	)		(9	)		(8	)
Net cash used in operating activities		(1,299	)		(1,858	)
Net cash (used in) provided by operating activities								(2,460	)		426
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in equipment and leasehold improvements		(376	)		(171	)		(690	)		(521	)
Net cash used in investing activities		(376	)		(171	)		(690	)		(521	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net draws (payments) on line of credit								1,300			(650	)
Net payments on debt – related party		—			(500	)		—			(500	)
Principal payments on long-term debt		(174	)		(174	)		(350	)		(349	)
Taxes paid related to net share settlement of restricted stock units		(3	)		(3	)		(10	)		(39	)
Net cash used in financing activities		(177	)		(677	)
Net cash provided by (used in) financing activities								940			(1,538	)
Net decrease in cash		(1,852	)		(2,706	)		(2,210	)		(1,633	)
Cash at beginning of period		2,589			3,767			2,589			3,767
Cash at end of period	$	737		$	1,061		$	379		$	2,134

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest	$	65		$	91		$	149		$	180
Income taxes	$	0		$	0		$	28		$	2

Cyanotech Corporation (the “Company”), located in Kailua-Kona, Hawaii, was incorporated in the state of Nevada on March 3, 1983 and is listed on the NASDAQ Capital Market under the symbol “CYAN”. The Company is engaged in the production of natural products derived from microalgae for the nutritional supplements market.

The Company is an agricultural company that produces high value natural products derived from microalgae grown in complex and intricate open-pond agricultural systems on the Kona coast of Hawaii. The Company's products include Hawaiian Spirulina Pacifica®, a superfood with numerous benefits, including boosting the immune system and overall cellular health; and BioAstin® Hawaiian Astaxanthin®, a powerful antioxidant shown to support and maintain the body's natural inflammatory response.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (“SEC”). These interim condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to present fairly the Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations, Condensed Consolidated Statements of Stockholders’ Equity and Condensed Consolidated Statements of Cash Flows for the periods presented in accordance with GAAP.

Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full fiscal year. The Condensed Consolidated Balance Sheet as of March 31, 2022 was derived from the audited consolidated financial statements. These condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended March 31, 2022, contained in the Company’s annual report on Form 10-K as filed with the SEC on June 22, 2022.

As of ~~June~~September 30, 2022, the Company had cash of ~~$737,000~~$379,000 and working capital of ~~$10,950,000~~$10,356,000 compared to $2,589,000 and $11,443,000, respectively, as of March 31, 2022. The Company has a Revolving Credit Agreement (“Credit Agreement”) with First Foundation Bank (“Bank”) that allows the Company to borrow up to $2,000,000 on a revolving basis. At ~~both~~ ~~June~~September 30, 2022 and March 31, 2022, the Company had 0$1,300,000 and $0, respectively, outstanding borrowings on the line of credit. The line of credit is subject to renewal on August 30, ~~2022~~2023 and the Company intends to renew or replace it with another line of credit on or before the expiration date. The Company also has a loan facility with a related party that allows the Company to borrow up to $500,000 on a revolving basis (the “Revolver”). At ~~June~~September 30, 2022 and March 31, 2022, the Company had 0no outstanding borrowings on the Revolver. The Revolver expires on April 12, 2024.

As of ~~June~~September 30, 2022, the Company had ~~$3,764,000~~$3,588,000 in long-term debt (“Term Loans”) payable to the Bank that require the payment of principal and interest monthly through August 2032. Pursuant to the Term Loans and the Credit Agreement, the Company is subject to annual financial covenants, customary affirmative and negative covenants and certain subjective acceleration clauses. As of March 31, 2022, the Company was in compliance with all required annual financial covenants under the Term Loans and the Credit Agreement.

In April 2019, the Company obtained a loan in the amount of $1,500,000 from a related party. The proceeds were used to pay down accounts payable and for general operating capital purposes. On April 12, 2021, the Company amended this loan (see Notes 65 and 1312). As of both ~~June~~September 30, 2022 and March 31, 2022, the Company had $1,000,000 outstanding on the related party note.

In the second quarter of fiscal 2023, the impacts from the macroeconomic environment have led to lower sales across all of the Company's portfolio and cash flows from operating activities. During this period, the Company drew $1,300,000 on its line of credit. To address the resulting cash flow challenges beginning in the third quarter of fiscal 2023, the Company has implemented some cost savings initiatives, including stopping or slowing production of inventory in alignment with current customer demand, reducing headcount and compensation, primarily through attrition and furloughs, respectively, and eliminating certain discretionary selling, general and administrative expenses.

Funds generated by operating activities and available cash are expected to continue to be the Company’s most significant sources of liquidity for working capital requirements, debt service and funding of maintenance levels of capital expenditures. The Company has developed its operating plan to produce the cash flows necessary to ~~grow its business and~~ meet all financing requirements. Although the Company has a history of either being in compliance with debt covenants or obtaining the necessary waivers, execution of its operating plan is dependent on many factors, some of which are not within the control of the Company. Consequently, future results may vary significantly from expected results.

The accompanying condensed consolidated financial statements include the accounts of Cyanotech Corporation and its wholly owned subsidiary, Nutrex Hawaii, Inc. (“Nutrex Hawaii” or “Nutrex”, collectively the “Company”). All intercompany balances and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of any contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the periods reported. Management reviews these estimates and assumptions periodically and reflects the effect of revisions in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions.

A significant portion of revenue and accounts receivable are derived from a few major customers. For the three months ended ~~June~~September 30, 2022, ~~two~~ ~~customers~~one customer individually accounted for ~~24% and 17%~~48% of the Company’s total net sales, and for the three months ended ~~June~~September 30, 2021, two customers individually accounted for ~~26%~~28% and ~~14%~~21% of the Company’s total net sales. For the six months ended September 30, 2022, two customers individually accounted for 35% and 10% of the Company’s total net sales, and for the six months ended September 30, 2021, two customers individually accounted for 21% and 16% of the Company’s total net sales. Two customers accounted for 76% and 63% of the Company’s accounts receivable balance as of ~~both~~ ~~June~~September 30, 2022 and March 31, ~~2022.~~2022, respectively.

The Company records revenue based on the five-step model which includes: (1) identifying the contract with the customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations; and (5) recognizing revenue when the performance obligations are satisfied. Substantially all of the Company’s revenue is generated by fulfilling orders for the purchase of our microalgal dietary supplements to retailers, wholesalers, or direct to consumers via online channels, with each order considered to be a distinct performance obligation. These orders may be formal purchase orders, verbal phone orders, e-mail orders or orders received online. Shipping and handling activities for which the Company is responsible under the terms and conditions of the order are not accounted for as performance obligations but as fulfillment costs. These activities are required to fulfill the Company’s promise to transfer the goods and are expensed when revenue is recognized.

Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling a performance obligation. The Company has elected to exclude sales, use and similar taxes from the measurement of the transaction price. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, which includes costs for trade promotion programs, coupons, returns and early payment discounts. Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. The Company reviews and updates these estimates at the end of each reporting period and the impact of any adjustments are recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, the Company considers the customer's ability and intent to pay that amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, typically 30 days from the invoice date, which occurs on the date of transfer of control of the products to the customer. Revenue is recognized at the point in time that control of the ordered products is transferred to the customer. Generally, this occurs when the product is delivered, or in some cases, picked up from one of the Company’s distribution centers by the customer. Revenue from extraction services is recognized when control is transferred upon completion of the extraction process.

Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the consolidated balance sheets. During the three months ended ~~June~~September 30, 2022 and 2021, the Company did not recognize any revenue from deposits that were included in contract liabilities as of March 31, 2022 and 2021, respectively. During the six months ended September 30, 2022 and 2021, the Company recognized $91,000 and $49,000, respectively, of revenue from deposits that were included in contract liabilities as of March 31, 2022 and 2021, respectively. The Company’s contracts have a duration of one year or less and therefore, the Company has elected the practical expedient of not disclosing revenues allocated to partially unsatisfied performance obligations.

The following table represents revenue disaggregated by major product line and extraction services for the:

In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which as part of its Simplification Initiative to reduce the cost and complexity in accounting for income taxes, removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted ASU 2019-12 as of April 1, 2021 with no impact on its consolidated financial statements and related disclosures.

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Inventories consist of the following as of:

The Company recognizes abnormal production costs, including fixed cost variances from normal production capacity, fixed production overhead costs, idle facilities, freight handling costs and spoilage, as an expense in the period incurred, without adjusting overhead absorption rates. Normal production capacity is defined as the production expected to be achieved over a number of periods or seasons under normal circumstances, taking into account the loss of capacity resulting from planned maintenance. The Company had 0no abnormal productions costs for the three months ended ~~June~~September 30, 2022 or 2021.

Beginning in fiscal 2021, cultivation of astaxanthin was completed in the first six months of the fiscal year during the most productive months of the year due to the best growing conditions, compared to year-round production in the prior fiscal years. A similar approach is being followed in fiscal year 2023. The Company calculates total production costs for the year based on normal capacity of production expected to be achieved in a year under normal circumstances. These costs are then allocated into inventory based on the period of production, not including abnormal production costs. Allocating fixed and overhead costs requires management’s judgement to determine when production is outside of the normal range of expected variation in production.

Other non-inventoriable fixed costs of ~~$35,000~~$34,000 and ~~$4,000~~$32,000 were expensed to cost of sales for the three months ended ~~June~~September 30, 2022 and 2021, respectively.

Management has determined 0that no asset impairment existed as of ~~June~~September 30, ~~2022~~2022. ~~and~~ ~~March 31, 2022,~~ ~~respectively.~~ Depreciation and amortization expense were approximately $417,000 and ~~$400,000~~$398,000 for the three months ended ~~June~~September 30, 2022 and 2021, respectively. Depreciation and amortization expense were approximately $834,000 and $798,000 for the six months ended September 30, 2022 and 2021, respectively.

On August 30, 2016, the Credit Agreement, which the Company entered into with the Bank on June 3, 2016, became effective after the Company and the Bank received the necessary approvals from the State of Hawaii to secure the lien on the Company’s leasehold property in Kona, Hawaii. The Credit Agreement allows the Company to borrow up to $2,000,000 on a revolving basis. Borrowings under the Credit Agreement bear interest at the Wall Street Journal prime rate ~~(3.5%~~(4.75% at ~~June~~September 30, 2022 and 3.25% at March 31, 2022) plus 2%, floating, provided that at no time shall the annual interest rate be less than 5.25%.

At ~~June~~September 30, 2022 and March 31, 2022, ~~there was 0~~the outstanding balance under the Credit ~~Agreement.~~Agreement was $1,300,000 and $0, respectively, and at September 30, 2022 was included in current liabilities on the Condensed Consolidated Balance Sheets. The line of credit, which is subject to annual renewal, was renewed on August 30, ~~2021~~2022 and will be subject to renewal upon expiration on August 30, ~~2022.~~2023.

The Credit Agreement grants the Bank the following security interests in the Company’s property: (a) a lien on the Company’s leasehold interest in its Kona facility; (b) an assignment of the Company’s interest in leases and rents on its Kona facility; and (c) a security interest in all fixtures, furnishings and equipment related to or used by the Company at the Kona facility. Each security interest is further subject to the terms of the Credit Agreement.

In 2015, the Company executed a loan agreement with a lender providing for $2,500,000 in aggregate credit facilities (the “2015 Loan”) secured by substantially all the Company’s assets, pursuant to a Term Loan Agreement dated July 30, 2015 (the “2015 Loan Agreement”). The 2015 Loan is evidenced by a promissory note in the amount of $2,500,000, the repayment of which is partially guaranteed under the provisions of the United States Department of Agriculture (“USDA”) Rural Development Guarantee program. The proceeds of the 2015 Loan were used to pay off a $500,000 short term note payable that matured on September 18, 2015, and to acquire new processing equipment and leasehold improvements at the Company’s Kona, Hawaii facility.

The provisions of the 2015 Loan require the payment of principal and interest until its maturity on September 1, 2022, the obligation fully amortizes over seven (7) years. Interest on the 2015 Loan accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate ~~(3.5%~~(4.75% and 3.25% at ~~June~~September 30, 2022 and March 31, 2022, respectively) plus 2.0% and is adjustable on the first day of each calendar quarter and fixed for that quarter, provided that at no time shall the annual interest rate be less than 6.0%. The 2015 Loan was paid off in September 2022 and the balance under the 2015 Loan was ~~$110,000 and~~ $218,000 at~~June 30, 2022~~ ~~and~~ March 31, 2022, ~~respectively,~~ and was included in long-term debt in the debt table above.

In 2012, the Company executed a loan agreement with a lender providing for $5,500,000 in aggregate credit facilities (the “2012 Loan”) secured by substantially all the Company’s assets, including a mortgage on the Company's interest in its lease at the National Energy Laboratory of Hawaii Authority, pursuant to a Term Loan Agreement dated August 14, 2012 (the “2012 Loan Agreement”). The 2012 Loan is evidenced by promissory notes in the amounts of $2,250,000 and $3,250,000, the repayment of which is partially guaranteed under the provisions of a USDA Rural Development Guarantee. The proceeds of the 2012 Loan were used to acquire processing equipment and leasehold improvements at its Kona, Hawaii facility.

The provisions of the 2012 Loan required the payment of interest only for the first 12 months of the term; thereafter, and until its maturity on August 14, 2032, the obligation fully amortizes over nineteen (19) years. Interest on the 2012 Loan accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate ~~(3.5%~~(4.75% and 3.25% at ~~June~~September 30, 2022 and March 31, 2022, respectively) plus 1.0% and is adjustable on the first day of each calendar quarter and fixed for that quarter, provided that at no time shall the annual interest rate be less than 5.5%. The balance under the 2012 Loan was ~~$3,654,000~~$3,588,000 and $3,720,000 at ~~June~~September 30, 2022 and March 31, 2022, respectively, and was included in long-term debt in the debt table above.

The 2015 Loan includes a one-time origination and guaranty fee totaling $113,900 and an annual renewal fee payable in the amount of 0.5% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year, beginning December 31, 2015. The USDA has guaranteed 80% of all amounts owing under the 2015 Loan. The 2012 Loan included a one-time origination and guaranty fees totaling $214,500 and an annual renewal fee payable in the amount of 0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year, beginning December 31, 2012. The USDA has guaranteed 80% of all amounts owing under the 2012 Loan. The balance in unamortized debt issuance costs was ~~$105,000~~$99,000 and $112,000 at ~~June~~September 30, 2022 and March 31, 2022, respectively.

The Company’s Credit Agreement, 2015 Loan and 2012 Loan are subject to annual debt service and other financial covenants, including covenants which require the Company to meet key financial ratios and customary affirmative and negative covenants. As of March 31, 2022, the Company was in compliance with all required annual financial covenants. The next remeasurement date will be March 31, 2023.

In April 2019, the Company obtained a loan in the amount of $1,500,000 and the interest was payable quarterly. The loan was originally due in April 2021. In April 2021, the Company amended the loan, which extended the expiration to April 2024, converted $500,000 into revolving loans, adjusted the interest rate to reflect a floor of 5%, and granted a security interest in substantially all of the Company’s personal property assets, subject to limited exceptions. Concurrently, with the amendment and conversion of the original loan, the Company repaid in cash the principal amount of $500,000 plus accrued interest to date of $1,900 (see Note 12). At ~~June~~September 30, 2022 and March 31, 2022, the balance under this loan was $1,000,000 and was included in long-term debt, in the debt table above. Interest accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate (4.75% and 3.25% at September 30, 2022 and March 31,2022, respectively) plus 1.0% and is ~~payable quarterly.~~adjustable on the first day of each calendar quarter and fixed for that quarter, provided that at no time shall the annual interest rate be less than 5.0%.

Future principal payments under the loans and finance lease obligations at ~~June~~September 30, 2022 are as follows:

The Company leases facilities, equipment and land under non-cancelable operating leases expiring through 2037. One of its facility leases contains price escalations and a renewal option for five years. Right-of-use assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Right-of-use assets and liabilities were recognized at April 1, 2019 based on the present value of lease payments over the lease term, using the Bank’s incremental borrowing rate based on the information available at recognition, and the Company has elected to exclude non-lease components. The Company also leases two 84-month solar leases, which are included in the right-of-use assets and liabilities. At ~~June~~September 30, 2022, the weighted average remaining lease terms was 12.1 years, the weighted average discount rate was 7.2%, and for the ~~three~~six months ended ~~June~~September 30, 2022 and 2021, the operating lease costs were ~~$171,000~~$344,000 and ~~$147,000,~~$296,000, respectively.

Supplemental balance sheet information related to leases consist of the following as of:

From time to time, the Company may be involved in litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. There were no significant legal matters outstanding at ~~June~~September 30, 2022.

The Company has share-based compensation plans, which are more fully described in Note 10, Share-Based Compensation, to the Consolidated Financial Statements included in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2022 as filed with the SEC on June 22, 2022.

As of ~~June~~September 30, 2022, the Company had two equity-based compensation plans: the 2016 Equity Incentive Plan (the “2016 Plan”) and the 2014 Independent Director Stock Option and Restricted Stock Grant Plan (the “2014 Directors Plan”). The Company has also issued stock options, which remain outstanding as of ~~June~~September 30, 2022, under ~~two~~an equity-based compensation ~~plans~~plan which ~~have~~has expired according to ~~their~~its terms: ~~the~~ ~~2005~~ ~~Stock Option Plan (the~~ ~~“2005~~ ~~Plan”) and~~ the 2004 Independent Director Stock Option and Stock Grant Plan (the “2004 Directors Plan”). ~~These plans~~The plan allowed the Company to award stock options and shares of restricted common stock to eligible employees, certain outside consultants and independent directors. ~~NaN~~No additional awards will be issued under the ~~2005~~ ~~Plan or the~~ 2004 Directors Plan.

The following table presents shares authorized, available for future grant and outstanding under each of the Company’s plans:

All stock option grants made under the equity-based compensation plans were issued at exercise prices no less than the Company’s closing stock price on the date of grant. Options under the 2016 ~~Plan,~~ ~~2005~~ Plan and 2014 Directors Plan were determined by the Board of Directors or the Compensation Committee of the Board of Directors in accordance with the provisions of the respective plans. The terms of each option grant include vesting, exercise, and other conditions set forth in a Stock Option Agreement evidencing each grant. No option can have a life in excess of ten (10) years. The Company records compensation expense for employee stock options based on the estimated fair value of the options on the date of grant using the Black-Scholes option-pricing model. The model requires various assumptions, including a risk-free interest rate, the expected term of the options, the expected stock price volatility over the expected term of the options, and the expected dividend yield. Compensation expense for employee stock options is recognized ratably over the vesting term. Compensation expense recognized for options issued under all Plans was ~~$17,000~~$24,000 and ~~$13,000~~$17,000 for the three months ended ~~June~~September 30, 2022 and 2021, respectively. Compensation expense recognized for options issued under all Plans was $41,000 and $30,000 for the six months ended September 30, 2022 and 2021, respectively.

A summary of option activity under the Company’s stock plans for the ~~three~~six months ended ~~June~~September 30, 2022 is presented below:

The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price optionees would have received if all options had been exercised on the last business day of the period indicated, based on the Company’s closing stock price of ~~$2.92~~$2.16 and $3.37 at ~~June~~September 30, 2022 and March 31, 2022, respectively.

A summary of the Company’s non-vested options for the ~~three~~six months ended ~~June~~September 30, 2022 is presented below:

The weighted average grant-date fair value of stock options granted during the ~~three~~six months ended ~~June~~September 30, 2022 was $97,000. As of ~~June~~September 30, 2022, total unrecognized stock-based compensation expense related to all unvested stock options was ~~$186,000,~~$166,000, which is expected to be expensed over a weighted average period of ~~2.3~~2.0 years.

Grants of fully vested restricted stock issued to Non-Employee Directors during the six months ended September 30, 2022 and 2021 were 64,489 and 0, respectively. Compensation expense recognized for fully vested restricted stock grants under the 2014 Directors Plan was $158,000 and $0 for both the three and six months ended September 30, 2022 and 2021, respectively.

RSUs are service-based awards granted to eligible employees under the 2016 Plan. Compensation expense recognized for RSUs issued under the 2016 Plan was ~~$5,000~~$17,000 and ~~$8,000~~$82,000 for the three months ended ~~June~~September 30, 2022 and 2021, respectively. Compensation expense recognized for RSUs issued under the 2016 Plan was $22,000 and $90,000 for the six months ended September 30, 2022 and 2021, respectively.

The following table summarizes information related to awarded RSUs for the ~~three~~six months ended ~~June~~September 30, 2022:

As of ~~June~~September 30, 2022, total unrecognized stock-based compensation expense related to unvested restricted stock units was ~~$17,000,~~$153,000, which is expected to be expensed over a weighted average period of ~~1.0~~2.7 years.

The Company utilizes its estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss). The Company recorded an income tax expense of ~~$3,000~~$0 and ~~$4,000~~$11,000 for the three months ended ~~June~~September 30, 2022 and 2021, respectively. The Company’s effective tax rate was ~~(0.7%)~~0% and ~~0.8%~~1.1% for the three months ended ~~June~~September 30, 2022 and 2021, respectively. The Company recorded an income tax expense of $3,000 and $14,000 for the six months ended September 30, 2022 and 2021, respectively. The Company’s effective tax rate was 0% and 1.0% for the six months ended September 30, 2022 and 2021, respectively. The effective tax rates for all periods differ from the statutory rate of 21% as a result of state taxes (net of federal benefit) and the net change in valuation allowance against the net deferred tax asset the Company believes is not more likely than not to be realized. The Company continues to carry a full valuation allowance on its net deferred tax assets.

The Company is subject to taxation in the United States and ~~seven~~eight state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events.

As of ~~June~~September 30, 2022 and 2021, there was 0no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its Consolidated Condensed Statements of Operations, which is consistent with the recognition of these items in prior reporting periods.

With few exceptions, the Company is no longer subject to U.S. federal, state, local, and non-U.S. income tax examination by tax authorities for tax years before 2018.

Basic earnings (loss) per share is computed on the basis of the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed on the basis of the weighted average number of common shares outstanding plus the potentially dilutive effect of outstanding stock options using the treasury stock method.

Reconciliations between the numerator and the denominator of the basic and diluted (loss) income per share computations for the three and sixmonths ended ~~June~~September 30, 2022 and 2021 are as follows:

Basic and diluted per share amounts are the same in periods of a net loss because common share equivalents are anti-dilutive when a net loss is recorded. Diluted earnings per share does not include the impact of common stock options and restricted stock units totaling ~~12,000~~5,000 for the three months ended ~~June~~September 30, 2022, and 7,000 for the six months ended September 30, 2022, as the effect of their inclusion would be anti-dilutive. Restricted stock units become dilutive within the period granted and remain dilutive until the units vest and are ~~issued as common stock.~~then included in the calculation of basic earnings per share. The denominator for effective dilutive shares for the prior year have been restated to conform to current year presentation, to included unvested restricted stock units that have a dilutive effect.

In April 2019, the Company obtained an unsecured subordinated loan from Skywords Family Foundation, Inc. (“Skywords”) in the principal amount of $1,500,000 pursuant to a Promissory Note (the "Skywords Note”) executed by the Company in favor of Skywords. Skywords is controlled by the Company’s Chairman of the Board of Directors and largest stockholder. The Skywords Note bore interest at a rate of 1% plus the prime rate (as published by the Wall Street Journal), which was recalculated and payable on a quarterly basis. The principal amount and any accrued and unpaid interest ~~was~~were due and payable on April 12, 2021. The proceeds of the Skywords Note were used to pay down accounts payable and for general operating capital purposes.

On April 12, 2021, the Company entered into an Amended and Restated Promissory Note (the “Skywords Amended Note”) with Skywords. The Company and Skywords agreed to amend, restate, replace and otherwise modify without novation, the Skywords Note in order to covert $500,000 of the outstanding principal amount into revolving loans that may be prepaid and reborrowed from time to time in principal amounts not to exceed $500,000, extend the maturity date by three years, adjust the interest rate to reflect a floor of 5% and secure Skywords’ interest by granting a security interest in substantially all of the Company’s personal property assets, subject to limited exceptions (the “Collateral”). On April 12, 2021, concurrently with the conversion, the Company repaid in cash to Skywords, the principal amount of $500,000 plus accrued interest to date of $1,900. The Skywords Amended Note bears interest at a rate of 1% plus the prime rate (as published by the Wall Street Journal), which will be recalculated and payable on a quarterly basis, provided that at no time shall the annual interest rate be less than 5%. The principal amount and any accrued and unpaid interest will be due and payable on April 12, 2024, unless accelerated in an event of default. The Company may prepay the Skywords Amended Note at any time without penalty.

On April 12, 2021, in connection with the grant of a security interest in the Collateral, the Company also entered into an Intercreditor and Subordination Agreement with the Bank and Skywords. The Company is indebted to the Bank pursuant to two Term Loans and a Credit Agreement, each of which granted the Bank a security interest in substantially all of the Company’s personal property assets. The Bank’s security interest in the Company’s personal property assets ranks senior to Skywords’ security interest in the Collateral, and the Intercreditor and Subordination Agreement generally governs the relationship between the Bank and Skywords as secured lenders to the Company and includes customary terms.

At both ~~June~~September 30, 2022 and March 31, 2022, the Skywords Note principal balance was $1,000,000, and was included in long-term debt on the Condensed Consolidated Balance Sheets. At September 30, 2022 and March 31, 2022, the interest rates were 5.75% and 5.0%, respectively.

We are a world leader in the production of high value natural products derived from microalgae. Incorporated in 1983, we are guided by the principle of providing beneficial, quality microalgal products for health and human nutrition in a sustainable, reliable and environmentally sensitive operation. We are Good Manufacturing Practices (“GMP”) certified by the Merieux NutriSciences, reinforcing our commitment to quality in our products, quality in our relationships (with our customers, suppliers, employees and the communities we live in), and quality of the environment in which we work. Our products include:

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Microalgae are a diverse group of microscopic plants that have a wide range of physiological and biochemical characteristics and contain, among other things, high levels of natural protein, amino acids, vitamins, pigments and enzymes. Microalgae have the following properties that make commercial production attractive: (1) microalgae grow much faster than land grown plants, often up to 100 times faster; (2) microalgae have uniform cell structures with no bark, stems, branches or leaves, permitting easier extraction of products and higher utilization of the microalgae cells; and (3) the cellular uniformity of microalgae makes it practical to control the growing environment in order to optimize a particular cell characteristic. Efficient and effective cultivation of microalgae requires consistent light, warm temperatures, low rainfall and proper chemical balance in a very nutrient-rich environment, free of environmental contaminants and unwanted organisms. This is a challenge that has motivated us to design, develop and implement proprietary production and harvesting technologies, systems and processes in order to commercially produce human dietary supplement products derived from microalgae.

Our production of these products at the 96-acre facility on the Kona Coast of the island of Hawaii provides several benefits. We selected the Keahole Point location in order to take advantage of relatively consistent warm temperatures, sunshine and low levels of rainfall needed for optimal cultivation of microalgae. This location also offers us access to cold deep ocean water, drawn from an offshore depth of 2,000 feet, which we use in our Ocean-Chill Drying system to eliminate the oxidative damage caused by standard drying techniques and as a source of trace nutrients for microalgal cultures. The area is also designated a Biosecure Zone, with tight control of organisms allowed into the area and free of genetically modified organisms (“GMO”). We believe that our technology, systems, processes and favorable growing location generally permit year-round harvest of our microalgal products in a cost-effective manner.

The following tables present selected consolidated financial data for each of the periods indicated ($ in thousands):

	Three Months Ended						Three Months Ended						Six Months Ended
	June 30,						September 30,						September 30,
	2022			2021			2022			2021			2022			2021
Net sales	$	6,716		$	8,964		$	5,179		$	9,419		$	11,895		$	18,383
Net sales decrease		25.1	%
Net sales (decrease) increase								(45.0	)%					(35.3	)%
Gross profit	$	2,318		$	3,672		$	1,790		$	3,762		$	4,108		$	7,434
Gross profit as % of net sales		34.5	%		41.0	%		34.6	%		39.9	%		34.5	%		40.4	%
Operating expenses	$	2,743		$	3,053		$	2,627		$	2,680		$	5,370		$	5,733
Operating expenses as % of net sales		40.8	%		34.1	%		50.7	%		28.5	%		45.1	%		31.2	%
Operating (loss) income	$	(425	)	$	619
Operating(loss) income							$	(837	)	$	1,082		$	(1,262	)	$	1,701
Operating (loss) income as % of net sales		(6.3	)%		6.9	%		(16.2	)%		11.5	%		(10.6	)%		9.3	%
Income tax expense	$	3		$	4		$	—		$	11		$	3		$	14
Net (loss) income	$	(472	)	$	520		$	(940	)	$	970		$	(1,412	)	$	1,491

*Net Sales* (in thousands)
	Three Months Ended										Three Months Ended
	June 30,				$			%			September 30,				$			%
	2022		2021		Change			Change			2022		2021		Change			Change
Packaged sales
Astaxanthin	$	3,524	$	4,040	$	(516	)		(12.8	)%	$	2,854	$	4,015	$	(1,161	)		(28.9	)%
Spirulina		1,511		2,742		(1,231	)		(44.9	)%		1,061		1,796		(735	)		(40.9	)%
Total Packaged sales	$	5,035	$	6,782	$	(1,747	)		(25.6	)%	$	3,915	$	5,811	$	(1,896	)		(32.6	)%

Bulk sales
Astaxanthin	$	494	$	405	$	89			22.0	%	$	333	$	509	$	(176	)		(34.6	)%
Spirulina		1,093		1,583		(490	)		(31.0	)%		784		2,985		(2,201	)		(73.7	)%
Total Bulk sales	$	1,587	$	1,988	$	(401	)		(20.2	)%	$	1,117	$	3,494	$	(2,377	)		(68.0	)%

Contract extraction revenue	$	94	$	194	$	(100	)		(51.5	)%	$	147	$	114	$	33			28.9	%

Total sales
Astaxanthin	$	4,018	$	4,445	$	(427	)		(9.6	)%	$	3,187	$	4,524	$	(1,337	)		(29.6	)%
Spirulina		2,604		4,325		(1,721	)		(39.8	)%		1,845		4,781		(2,936	)		(61.4	)%
Contract extraction revenue		94		194		(100	)		(51.5	)%		147		114		33			28.9	%
Total sales	$	6,716	$	8,964	$	(2,248	)		(25.1	)%	$	5,179	$	9,419	$	(4,240	)		(45.0	)%

Net Sales The net sales decrease of ~~25.1%~~45.0% for the current quarter compared to the same period last year was primarily driven by a decrease in spirulina and astaxanthin packaged sales and spirulina bulk ~~sales~~sales. During the period, we experienced overall lower demand resulting from higher inflation and ~~contract extraction sales. The decrease~~consumers reducing spend in ~~both spirulina and astaxanthin~~non-discretionary areas. Our international customers have delayed, or reduced orders based on the appreciation of the U.S. dollar impacting exchange rates. Given the lower demand combined with global supply chain constraints, our bulk customers have higher than normal inventory levels. For our packaged sales, in addition to the ~~current quarter~~macroeconomics impacts, there was ~~primarily due to decreased~~a decrease in sales due to timing of shipments to a significant ~~customer as we transitioned to their selling platform~~customer. As a result, in the ~~prior year, offset by strong sales to key existing customers. Sales of bulk products were lower due to lower demand by our top customer for~~current fiscal quarter, consumer movement is not fully reflected in the ~~quarter coupled with timing of orders from other customers.~~packaged sales.

Gross Profit Gross profit as a percent of net sales for the second quarter of fiscal 2023 decreased by ~~6.5~~5.3 percentage points compared to the same period last year, which was the result of higher costs per kilogram of astaxanthin and spirulina due to the impact of inflation on our underlying costs and a slow start up of astaxanthin production in the current fiscal year related to staffing shortages.

Operating Expenses Operating expenses decreased by $0.1 million, or 2.0%, for the current year second quarter compared to the prior year same quarter, primarily due to lower incentive compensation expense resulting from net operating loss in the current quarter versus operating income in the prior year.

Income Taxes We recorded a state income tax expense of $0 for the second quarter of this fiscal year compared to an income tax expense of $11,000 for the same period last year. We continue to carry a full valuation allowance on our net deferred tax assets.

Net Sales The net sales decrease of 35.3% for the first six month of the fiscal 2023 compared to the same period last year was primarily driven by a decrease in spirulina and astaxanthin packaged sales and spirulina bulk sales. During the current period, we experienced overall lower demand resulting from higher inflation and consumers reducing spend in non-discretionary areas. Our international customers have delayed, or reduced orders based on the appreciation of the U.S. dollar impacting exchange rates. Given the lower demand combined with global supply chain constraints, our bulk customers have higher than normal inventory levels. For our packaged sales, in addition to the macroeconomic impacts, there was a decrease in sales due to the timing of shipments to a significant customer, as ~~well~~we transition to their selling platform in the prior year same period. As a result, in the current period, consumer movement is not fully reflected in the packaged sales.

Gross Profit Gross profit as a percent of net sales decreased by 5.9 percentage points compared to the same period last year, which was the result of higher costs per kilogram of astaxanthin and spirulina due to the impact of inflation on our underlying costs and customer mix.

Operating Expenses Operating expenses decreased by ~~$0.3~~$0.4 million, or ~~10.2%~~6.3%, for the ~~current year~~ first ~~quarter~~six months of fiscal 2023 compared to the prior year same ~~quarter,~~period, primarily due to ~~marketing mix.~~lower advertising costs and lower incentive compensation expense resulting from net operating losses in the current year versus operating income in the prior year.

Income Taxes We recorded a state income tax expense of $3,000 for the first ~~quarter~~six months of ~~this~~ fiscal ~~year~~2023 compared to an income tax expense of ~~$4,000~~$14,000 for the same period last year. We continue to carry a full valuation allowance on our net deferred tax assets.

As of ~~June~~September 30, 2022, we had cash of ~~$0.7~~$0.4 million and working capital of ~~$11.0~~$10.4 million compared to $2.6 million and $11.4 million, respectively, at March 31, 2022. We have a Credit Agreement with the Bank that allows us to borrow up to $2.0 million on a revolving basis. At ~~June~~September 30, 2022 and March 31, 2022, we had no$1.3 million and $0, respectively, outstanding borrowings on the line of credit. The line of credit is subject to renewal on August 30, ~~2022,~~2023, and we intend to renew or replace it with another line of credit on or before the expiration date. We also have a loan facility with a related party that allows us to borrow up to $0.5 million ~~of borrowing capacity under~~on the ~~Revolver with Skywords Family Foundation.~~Revolver. At ~~June~~September 30, 2022 and March 31, 2022, we had no outstanding borrowings on the Revolver. The Revolver expires on April 12, 2024.

As of ~~June~~September 30, 2022, we had ~~$3.8~~$3.6 million in Term Loans payable to the Bank that require the payment of principal and interest monthly through August 2032. Pursuant to the Term Loans and the Credit Agreement, we are subject to annual financial covenants, customary affirmative and negative covenants and certain subjective acceleration clauses. As of March 31, 2022, we were in compliance with all required annual financial covenants under the Term Loans and the Credit Agreement.

In April 2019, we obtained a loan in the amount of $1.5 million from a related party. The proceeds were used to pay down accounts payable and for general operating capital purposes. On April 12, 2021, we amended this loan (see Notes 5 and 12 in the Notes to Condensed Consolidated Financial Statements). As of both September 30, 2022 and March 31, 2022, we had $1.0 million outstanding on the related party note.

Funds generated by operating activities and available cash are expected to continue to be our most significant sources of liquidity for working capital requirements, debt service and funding of maintenance levels of capital expenditures. We have developed our operating plan to produce the cash flows necessary to ~~grow our business and~~ meet all financing requirements. Although we have a history of either being in compliance with debt covenants or obtaining the necessary waivers, execution of our operating plan is dependent on many factors, some of which are not within the control of the Company. Consequently, future results may vary significantly from expected results.

Cash Flows The following table summarizes our cash flows for the periods indicated ($ in thousands):

Cash used in operating activities for the ~~three~~six months ended ~~June~~September 30, 2022 was the result of a net loss of ~~$0.5~~$1.4 million, an increase of ~~$1.2~~$2.6 million in inventories, offset by non-cash charges of ~~$0.5~~$1.3 million.

Cash used in investing activities for the ~~three~~six months ended ~~June~~September 30, 2022 primarily includes costs for acquiring equipment ~~and leasehold improvements~~ at our Kona facility.

Cash ~~used in~~provided by financing activities for the ~~three~~six months ended ~~June~~September 30, 2022 consists primarily of draws on the line of credit of $1.3 million, offset by debt service payments of ~~$0.2~~$0.4 million.

As of ~~June~~September 30, 2022, our working capital was ~~$11.0~~$10.4 million, a decrease of ~~$0.4~~$1.0 million compared to March 31, 2022. There was an increase in inventories in the first ~~quarter~~six months of fiscal 2023, due to lower bulk sales and as we commence cultivation of astaxanthin. Cultivation improvements that we have made allow us to produce all of the required demand for astaxanthin during the most favorable growing season.

Our results of operations and financial condition can be affected by numerous factors, many of which are beyond our control and could cause future results of operations to fluctuate materially as it has in the past. Future operating results may fluctuate as a result of changes in sales volumes to our largest customers, weather patterns, increased competition, increased materials, nutrient and energy costs, government regulations and other factors beyond our control.

A significant portion of our expense levels are relatively fixed, so the timing of increases in expenses is based in large part on forecasts of future sales. If net sales are below expectations in any given period, the adverse impact on results of operations may be magnified by our inability to adjust spending quickly enough to compensate for the sales shortfall. We may also choose to reduce prices or increase spending in response to market conditions, which may have a material adverse effect on financial condition and results of operations.

Based upon our current operating plan, analysis of our consolidated financial position and projected future results of operations, we believe that our operating cash flows, cash balances and working capital will be sufficient to finance current operating requirements, debt service requirements, and routine planned capital expenditures, for the next twelve (12) months.

This outlook section contains a number of forward-looking statements, all of which are based on current expectations. Actual results may differ materially.

Our strategic direction has been to position as a world leader in the production and marketing of high-value natural products from microalgae. We are vertically aligned, producing raw materials in the form of microalgae processed at our 96-acre facility in Hawaii, and integrating those raw materials into finished products. Our primary focus is stabilizing our production volume, rationalizing market channel participation, and leveraging our centers of core competence. We will continue to place emphasis on our Nutrex Hawaiian consumer products while exploring further opportunities for bulk sales orders for Spirulina and Astaxanthin, both domestically and internationally. Extraction services to third party customers utilizing our 1,000 bar super critical CO2 extractor process are expected to generate additional income throughout the year. We will leverage our experience and reputation for quality, nutritional products which promote health and well-being. The foundation of our nutritional products is naturally cultivated Hawaiian Spirulina Pacifica® in powder and tablet form; and BioAstin®Hawaiian Astaxanthin® antioxidant in extract and softgel form. Information about our Company and our products can be viewed at www.cyanotech.com and www.nutrex-hawaii.com. Consumer products can also be purchased online at www.nutrex-hawaii.com.

Gross profit margin percentages going forward can be impacted by lower production volumes along with pressure on input costs as well as greater competition in the market place. This could cause margins to decline in future periods. We will continue to focus on higher margin consumer products that promote health and well-being and strive for continuous improvements in processes and production methods to stabilize costs and production levels for the future. However, significant sales variability between periods may occur based on historical results.

Producing the highest quality microalgae is a complex biological process which requires balancing numerous factors including microalgal strain variation, temperature, acidity, nutrient and other environmental considerations, some of which are not within our control. An imbalance or unexpected event can occur resulting in production levels below normal capacity. The allocation of fixed production overheads (such as depreciation, rent and general insurance) to inventories is determined based on normal production capacity. When our production volumes are below normal capacity limits, certain fixed production overhead costs cannot be inventoried and are recorded immediately in cost of sales. In addition, when production costs exceed historical averages, we evaluate whether such costs are one-time-period charges or an ongoing component of inventory cost.

To manage our cash resources effectively, we will balance production with sales demand, minimizing the cost associated with inventory levels when appropriate and manage our expenses judiciously. We could experience unplanned cash outflows and may need to utilize other cash resources to meet working capital needs. A prolonged downturn in sales could impair our ability to generate sufficient cash for operations and hamper our ability to attract additional capital investment which could become necessary to maintain optimal production levels and efficiencies.

Our future results of operations and the other forward-looking statements contained in this Outlook, in particular the statements regarding revenues, gross margin and capital spending, involve a number of risks and uncertainties. In addition to the factors discussed above, any of the following could cause actual results to differ materially: business conditions and growth in the natural products industry and in the general economy; changes in customer order patterns; changes in demand for natural products in general; changes in weather conditions; changes in health and growing conditions of our astaxanthin and spirulina products; competitive factors, such as increased production capacity from competing spirulina and astaxanthin producers and the resulting impact, if any, on world market prices for these products; government actions and increased regulations both domestic and foreign; shortage of manufacturing capacity; and other factors beyond our control. Risk factors are discussed in detail in Part II, Item 1A of this quarterly report and in Part I, Item 1A of our Form 10-K report for the year ended March 31, 2022.

We believe that our technology, systems, processes and favorable growing location generally permit year-round harvest of our microalgal products in a cost-effective manner. However, previously experienced imbalances in the highly complex biological production systems, together with volatile energy costs and rapidly changing world markets, suggest a need for continuing caution with respect to variables beyond our reasonable control. Therefore, we cannot, and do not attempt to, provide any definitive assurance with regard to our technology, systems, processes, location, or cost-effectiveness.

As of ~~June~~September 30, 2022, we had no off-balance sheet arrangements or obligations.

Inflationary factors such as increases in the costs of materials, utilities and labor ~~directly affect~~are affecting our operations. ~~While we~~We are also experiencing overall lower demand as consumers are feeling the impacts of higher inflation and reducing spend in non-discretionary areas. Our international customers have ~~experienced some cost inflation~~delayed, or reduced orders based on the appreciation of the US dollar impacting exchange rates. Given the lower demand, our bulk customers have higher than normal inventory levels. The exact impact on our ~~inputs, it has not had a material effect on our financial~~ results ~~for~~is difficult to isolate and quantify given the ~~current quarter.~~macroeconomic environment. Most of our leases provide for cost-of-living adjustments and require us to pay for insurance and maintenance expenses, all of which are subject to inflation. Additionally, our future lease cost for new facilities may include potentially escalating costs of real estate and construction. There is no assurance that we will be able to pass on increased costs to our customers.

Depreciation expense is based on the historical cost of fixed assets and is therefore potentially less than it would be if it were based on current replacement cost. While property and equipment acquired in prior years will ultimately have to be replaced at higher prices, it is expected that replacement will be a gradual process over many years.

Our critical accounting policies and estimates are disclosed in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the fiscal year ended March 31, 2022 filed with the SEC on June 22, 2022. In the ~~three~~six months ended ~~June~~September 30, 2022, there were no changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K.

Under the supervision and with the participation of our management, including our chief executive officer (“CEO”) and chief financial officer (“CFO”), we have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15(d)-15(e) of the Exchange Act as of the end of the period covered by this Report. Based on that evaluation, our CEO and CFO have concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosures.

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our management evaluated the effectiveness of our internal control over financial reporting as of ~~June~~September 30, 2022. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in “Internal Control - Integrated Framework” (2013 Framework). Based on our assessment, using those criteria, management concluded that our internal control over financial reporting was effective as of ~~June~~September 30, 2022.

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the ~~three~~six months ended ~~June~~September 30, 2022 that has materially affected, or was reasonably likely to materially affect, our internal control over financial reporting.

Our management, including our CEO and CFO, do not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.

The inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, or by collusion of two or more people. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

This Form 10-Q should be read in conjunction with Item 9A “Controls and Procedures” of the Company’s Form 10-K for the fiscal year ended March 31, 2022, filed June 22, 2022.

From time to time, the Company may be involved in litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. There were no significant legal matters outstanding at ~~June~~September 30, 2022.

For a discussion of the risk factors relating to our business, please refer to Part I, Item 1A of our Form 10-K for the year ended March 31, 2022, which is incorporated by reference herein.

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	4
	Condensed Consolidated Balance Sheets as of ~~June~~September 30, 2022 and March 31, 2022 (unaudited)	4
	Condensed Consolidated Statements of Operations for the three and six months ended ~~June~~September 30, 2022 and 2021 (unaudited)	5
	Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended ~~June~~September 30, 2022 and 2021 (unaudited)	6
	Condensed Consolidated Statements of Cash Flows for the ~~three~~six months ended ~~June~~September 30, 2022 and 2021 (unaudited)	7
	Notes to Condensed Consolidated Financial Statements (unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1719
Item 4.	Controls and Procedures	2124

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	2225
Item 1A	Risk Factors	2225
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2225
Item 3.	Defaults upon Senior Securities	2225
Item 5.	Other Information	2225
Item 6.	Exhibits	2326

SIGNATURES		2427

	Three Months Ended June 30,						Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021			2022			2021

Net sales	$	6,716		$	8,964		$	5,179		$	9,419		$	11,895		$	18,383
Cost of sales		4,398			5,292			3,389			5,657			7,787			10,949
Gross profit		2,318			3,672			1,790			3,762			4,108			7,434

Operating expenses:
General and administrative		1,329			1,347			1,279			1,422			2,608			2,768
Sales and marketing		1,168			1,550			1,142			1,131			2,310			2,681
Research and development		246			156			206			127			452			284
Total operating expenses		2,743			3,053			2,627			2,680			5,370			5,733

(Loss) income from operations		(425	)		619			(837	)		1,082			(1,262	)		1,701

Interest expense, net		(44	)		(95	)		(103	)		(101	)		(147	)		(196	)

(Loss) income before income taxes		(469	)		524			(940	)		981			(1,409	)		1,505

Income tax expense		3			4			—			11			3			14

Net (loss) income	$	(472	)	$	520		$	(940	)	$	970		$	(1,412	)	$	1,491

Net (loss) income per share:
Basic	$	(0.08	)	$	0.09		$	(0.15	)	$	0.16		$	(0.23	)	$	0.24
Diluted	$	(0.08	)	$	0.08		$	(0.15	)	$	0.16		$	(0.23	)	$	0.24

Shares used in calculation of net (loss) income per share:
Basic		6,204			6,117			6,228			6,130			6,216			6,124
Diluted		6,204			6,293			6,228			6,139			6,216			6,136

($ in thousands)	Six Months Ended September 30, 2022		Six Months Ended September 30, 2021
Packaged sales
Astaxanthin packaged	$	6,379	$	8,054
Spirulina packaged		2,572		4,538
Total packaged sales		8,951		12,592

Bulk sales
Astaxanthin bulk		827		914
Spirulina bulk		1,877		4,569
Total bulk sales		2,704		5,483

Contract extraction revenue		240		308
Total net sales	$	11,895	$	18,383

	June 30, 2022		March 31, 2022		September 30, 2022		March 31, 2022
	(in thousands)				(in thousands)
Raw materials	$	2,125	$	1,490	$	1,843	$	1,490
Work in process		2,244		2,868		4,461		2,868
Finished goods		5,788		4,595		5,349		4,595
Supplies		542		513		435		513
Inventories	$	10,699	$	9,466	$	12,088	$	9,466

	June 30, 2022			March 31, 2022			September 30, 2022			March 31, 2022
	(in thousands)						(in thousands)
Equipment	$	20,386		$	20,231		$	20,493		$	20,231
Leasehold improvements		14,786			14,751			14,786			14,751
Furniture and fixtures		401			394			401			394
		35,573			35,376			35,680			35,376
Less accumulated depreciation and amortization		(24,756	)		(24,339	)		(25,164	)		(24,339	)
Construction-in-progress		1,099			848			1,231			848
Equipment and leasehold improvements, net	$	11,916		$	11,885		$	11,747		$	11,885

($ in thousands)	Three Months Ended June 30, 2022		Three Months Ended June 30, 2021
Packaged sales
Astaxanthin packaged	$	3,524	$	4,040
Spirulina packaged		1,511		2,742
Total packaged sales		5,035		6,782

Bulk sales
Astaxanthin bulk		494		405
Spirulina bulk		1,093		1,583
Total bulk sales		1,587		1,988

Contract extraction revenue		94		194
Total net sales	$	6,716	$	8,964

($ in thousands)	Three Months Ended September 30, 2022		Three Months Ended September 30, 2021
Packaged sales
Astaxanthin packaged	$	2,854	$	4,015
Spirulina packaged		1,061		1,796
Total packaged sales		3,915		5,811

Bulk sales
Astaxanthin bulk		333		509
Spirulina bulk		784		2,985
Total bulk sales		1,117		3,494

Contract extraction revenue		147		114
Total net sales	$	5,179	$	9,419

Payments Due	(in thousands)
Remainder of 2023	$	386
2024		291
2025		1,308
2026		325
2027		344
Thereafter		2,110
Total principal payments	$	4,764

Operating leases	Balance Sheet Classification	June 30, 2022			March 31, 2022			Balance Sheet Classification	September 30, 2022			March 31, 2022
		(in thousands)							(in thousands)
Right-of-use assets	Operating lease right-of-use assets	$	4,720		$	4,720		Operating lease right-of-use assets	$	4,720		$	4,720
Accumulated lease amortization	Operating lease right-of-use assets		(1,038	)		(933	)	Operating lease right-of-use assets		(1,147	)		(933	)

Total right-of-use assets	Total right-of-use assets	$	3,682		$	3,787		Total right-of-use assets	$	3,573		$	3,787

Current lease liabilities	Operating lease obligations	$	344		$	393		Operating lease obligations	$	294		$	393
Non-current lease liabilities	Long-term operating lease obligations		3,325			3,386		Long-term operating lease obligations		3,265			3,386

Total lease liabilities	Total lease liabilities	$	3,669		$	3,779		Total lease liabilities	$	3,559		$	3,779

Payments	(in thousands)			(in thousands)
Remainder of 2023	$	443		$	268
2024		480			480
2025		474			465
2026		441			439
2027		437			437
Thereafter		3,235			3,246
Total undiscounted lease payments		5,510			5,335
Less: present value discount		(1,841	)		(1,776	)
Total lease liability balance	$	3,669		$	3,559

	As of June 30, 2022						As of September 30, 2022
	Authorized		Available		Outstanding		Authorized		Available		Outstanding

2016 Plan		1,300,000		944,938		247,868		1,300,000		879,875		306,896
2014 Directors Plan		650,000		287,695		12,000		650,000		223,206		12,000
2005 Plan		—		—		49,500
2004 Directors Plan		—		—		6,000		—		—		6,000
Total		1,950,000		1,232,633		315,368		1,950,000		1,103,081		324,896

Option Activity	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value		Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at March 31, 2022		252,500	$	3.34		6.5	$	159,650		252,500		$	3.34		6.5	$	159,650
Granted		50,000	$	3.43						50,000		$	3.43
Outstanding at June 30, 2022		302,500	$	3.36		6.9	$	78,400
Exercisable at June 30, 2022		127,500	$	4.17		4.3	$	25,316
Expired										(49,500	)	$	5.80
Outstanding at September 30, 2022										253,000		$	2.88		8.0	$	250
Exercisable at September 30, 2022										111,333		$	2.90		7.1	$	250

Nonvested Options	Shares			Weighted Average Grant-Date Fair Value		Shares			Weighted Average Grant-Date Fair Value
Nonvested at March 31, 2022		141,667		$	1.33		141,667		$	1.33
Granted		50,000			1.94		50,000			1.94
Vested		(16,667	)		1.60		(50,000	)		1.33
Nonvested at June 30, 2022		175,000		$	1.48
Nonvested at September 30, 2022							141,667		$	1.55

Nonvested Restricted Stock Units	Shares			Weighted Average Grant Price		Shares			Weighted Average Grant Price
Nonvested restricted stock units at March 31, 2022		14,465		$	2.22		14,465		$	2.22
Granted		850			3.03		66,423			3.13
Vested		(2,277	)		2.29		(8,312	)		2.35
Forfeited		(170	)		2.52		(680	)		2.82
Nonvested restricted stock units at June 30, 2022		12,868		$	2.26
Nonvested restricted stock units at September 30, 2022							71,896		$	3.04

	Three Months Ended June 30, 2022
	Net Loss			Shares		Per Share
	(Numerator)			(Denominator)		Amount
	(in thousands)
Basic and diluted loss per share	$	(472	)		6,204	$	(0.08	)

	Three Months Ended September 30, 2022
	Net Loss			Shares		Per Share
	(Numerator)			(Denominator)		Amount
	(in thousands)
Basic and diluted loss per share	$	(940	)		6,228	$	(0.15	)

	Three Months Ended June 30, 2021						Three Months Ended September 30, 2021
	Net Income		Shares		Per Share		Net Income		Shares		Per Share
	(Numerator)		(Denominator)		Amount		(Numerator)		(Denominator)		Amount
	(in thousands)						(in thousands)
Basic income per share	$	520		6,117	$	0.09	$	970		6,130	$	0.16
Effective dilutive securities – common stock options and restricted stock units		—		176		—		—		9		—
Diluted income per share	$	520		6,293	$	0.08	$	970		6,139	$	0.16

	Six Months Ended September 30, 2022
	Net Loss			Shares		Per Share
	(Numerator)			(Denominator)		Amount
	(in thousands)
Basic and diluted loss per share	$	(1,412	)		6,216	$	(0.23	)

	Six Months Ended September 30, 2021
	Net Income		Shares		Per Share
	(Numerator)		(Denominator)		Amount
	(in thousands)
Basic income per share	$	1,491		6,124	$	0.24
Effective dilutive securities – common stock options and restricted stock units		—		12		—
Diluted income per share	$	1,491		6,136	$	0.24

	~~10.1~~	Executive Employment Agreement, dated as of June 16, 2022, by and between Mathhew K. Custer and Cyanotech Corporation (Incorporated by reference as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 22, 2022

	31.1*	Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of ~~August 10,~~November 9, 2022

	31.2*	Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of ~~August 10,~~November 9, 2022

	32*	Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 signed as of ~~August 10,~~November 9, 2022

	99.1*	Press Release dated ~~August 10,~~November 9, 2022

	101	The following financial statements from Cyanotech Corporation’s Quarterly Report on Form 10-Q for the quarter ended ~~June~~September 30, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.

	104	Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101)

		*Included herewith. Other exhibits were filed as shown above.

	CYANOTECH CORPORATION
	(Registrant)


~~August 10,~~November 9, 2022	By:	/s/ Matthew K. Custer
(Date)		Matthew K. Custer
		President and Chief Executive Officer


~~August 10,~~November 9, 2022	By:	/s/ Felicia Ladin
(Date)		Felicia Ladin
		Chief Financial Officer, Vice President — Finance & Administration, and Treasurer
		(Principal Financial Officer)

Exhibit Number		Description
~~10.1~~		Executive Employment Agreement, dated as of June 16, 2022, by and between Mathhew K. Custer and Cyanotech Corporation (Incorporated by reference as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 22, 2022

31.1*		Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of ~~August 10,~~November 9, 2022

31.2*		Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of ~~August 10,~~November 9, 2022

32*		Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 signed as of ~~August 10,~~November 9, 2022

99.1*		Press Release dated ~~August 10,~~November 9, 2022

101		The following financial statements from Cyanotech Corporation’s Quarterly Report on Form 10-Q for the quarter ended ~~June~~September 30, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Stockholders’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements

104		Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101)

		*Included herewith. Other exhibits were filed as shown above.